环磷酰胺 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "环磷酰胺" in Chinese language version.
refsWebsite
Global rank
Chinese rank
11th place
332nd place
1st place
1st place
6th place
4th place
621st place
1,608th place
710th place
776th place
209th place
356th place
1,684th place
696th place
102nd place
492nd place
low place
9,960th place
6,663rd place
8,533rd place
low place
low place
18th place
57th place
163rd place
188th place
5th place
12th place
8,869th place
low place
aacrjournals.org
cancerres.aacrjournals.org
- Brock N. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Research. January 1989, 49 (1): 1–7. PMID 2491747.
archive.org
- Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. The Journal of Rheumatology. February 1991, 18 (2): 188–94. PMID 1673721.
- Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clinics in Chest Medicine. March 1990, 11 (1): 31–54. PMID 1691069. doi:10.1016/S0272-5231(21)00670-5.
- Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney International. April 2002, 61 (4): 1495–501. PMID 11918757. doi:10.1046/j.1523-1755.2002.00279.x
. - Donelli MG, Bartosek I, Guaitani A, Martini A, Colombo T, Pacciarini MA, Modica R. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect. Cancer Treatment Reports. April 1976, 60 (4): 395–401. PMID 1277213.
- Friedman OM, Wodinsky I, Myles A. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective. Cancer Treatment Reports. April 1976, 60 (4): 337–46. PMID 1277209.
aspetjournals.org
jpet.aspetjournals.org
- Cohen JL, Jao JY. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. The Journal of Pharmacology and Experimental Therapeutics. August 1970, 174 (2): 206–10 [2014-05-02]. PMID 4393764. （原始内容存档于2021-08-28）.
cancer.gov
- NCI Drug Dictionary. National Cancer Institute. 2011-02-02 [2016-12-20]. （原始内容存档于2015-04-25）.
doi.org
- Pagnoux C. Updates in ANCA-associated vasculitis. European Journal of Rheumatology. September 2016, 3 (3): 122–133. PMC 5058451 . PMID 27733943. doi:10.5152/eurjrheum.2015.0043.
- King, Catherine; Harper, Lorraine. Avoidance of Harm From Treatment for ANCA-Associated Vasculitis. Current Treatment Options in Rheumatology. 2017-11-13, 3 (4): 230–243 [2025-02-27]. doi:10.1007/s40674-017-0082-y.
- La Mantia L, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. The Cochrane Database of Systematic Reviews. January 2007, 2007 (1): CD002819. PMC 8078225 . PMID 17253481. doi:10.1002/14651858.CD002819.pub2.
- Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology. April 2017, 56 (suppl_1): i100–i113. PMC 5850311 . PMID 28375452. doi:10.1093/rheumatology/kew417.
- Singh JA, Hossain A, Kotb A, Wells GA. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Systematic Reviews. September 2016, 5 (1): 155. PMC 5020478 . PMID 27619512. doi:10.1186/s13643-016-0328-z .
- Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American Journal of Hematology. December 2014, 89 (12): 1132–40. PMID 25407896. S2CID 85480421. doi:10.1002/ajh.23828.
- Or-Geva N, Reisner Y. The evolution of T-cell depletion in haploidentical stem-cell transplantation. British Journal of Haematology. March 2016, 172 (5): 667–84. PMID 26684279. S2CID 1093277. doi:10.1111/bjh.13868 .
- Fuchs EJ. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplantation. June 2015, 50 (Suppl 2): S31–6. PMC 4634886 . PMID 26039204. doi:10.1038/bmt.2015.92.
- Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Seminars in Hematology. April 2016, 53 (2): 90–7. PMC 4806368 . PMID 27000732. doi:10.1053/j.seminhematol.2016.01.005.
- Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?. American Journal of Medical Genetics. September 1999, 86 (3): 237–41. PMID 10482872. doi:10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V .
- Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984, 41 (3): 180–4. PMID 6374556. doi:10.1159/000225819.
- Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Medicine. September 2016, 14 (1): 137. PMC 5022202 . PMID 27623861. doi:10.1186/s12916-016-0673-8 .
- Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clinics in Chest Medicine. March 1990, 11 (1): 31–54. PMID 1691069. doi:10.1016/S0272-5231(21)00670-5.
- Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. American Journal of Respiratory and Critical Care Medicine. December 1996, 154 (6 Pt 1): 1851–6. PMID 8970380. doi:10.1164/ajrccm.154.6.8970380.
- Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. Journal of Clinical Oncology. October 2005, 23 (30): 7685–96. PMID 16234530. doi:10.1200/JCO.2005.08.789.
- Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Archives of Internal Medicine. March 1985, 145 (3): 548–9. PMID 3977522. doi:10.1001/archinte.145.3.548.
- Salido M, Macarron P, Hernández-García C, D'Cruz DP, Khamashta MA, Hughes GR. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus. 2003, 12 (8): 636–9. PMID 12945725. S2CID 26125211. doi:10.1191/0961203303lu421cr.
- Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Reviews. Clinical Oncology. November 2009, 6 (11): 638–47. PMID 19786984. S2CID 18219134. doi:10.1038/nrclinonc.2009.146.
- Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis and Rheumatism. January 2010, 62 (1): 9–21. PMID 20039416. doi:10.1002/art.25061.
- Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. September 1992, 340 (8822): 741–5. PMID 1356175. S2CID 8800101. doi:10.1016/0140-6736(92)92292-n.
- Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis and Rheumatism. September 1996, 39 (9): 1475–82. PMID 8814058. doi:10.1002/art.1780390906.
- Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis and Rheumatism. July 2008, 59 (7): 1034–9. PMID 18576286. doi:10.1002/art.23822.
- Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. European Journal of Clinical Investigation (Review). March 2015, 45 (3): 346–68. PMID 25627555. S2CID 870510. doi:10.1111/eci.12410 .
- Balow JE, Austin HA, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH. NIH conference. Lupus nephritis. Annals of Internal Medicine. January 1987, 106 (1): 79–94. PMID 3789582. doi:10.7326/0003-4819-106-1-79.
- Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clinical Pharmacokinetics. 2002, 41 (7): 485–504. PMID 12083977. S2CID 10873321. doi:10.2165/00003088-200241070-00003.
- Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Archives of Internal Medicine. February 2008, 168 (4): 378–81. PMID 18299492. doi:10.1001/archinternmed.2007.107 .
- Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Kwoh CK. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis and Rheumatism. August 1995, 38 (8): 1120–7. PMID 7639809. doi:10.1002/art.1780380815.
- Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology. American Society of Hematology. Education Program. 2007, 2007: 453–9. PMID 18024664. doi:10.1182/asheducation-2007.1.453 .
- Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design. Pharmacological Reviews. September 2011, 63 (3): 750–71. PMID 21737530. S2CID 25381232. doi:10.1124/pr.110.003459.
- Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clinical Pharmacokinetics. April 2000, 38 (4): 291–304. PMID 10803453. S2CID 39787288. doi:10.2165/00003088-200038040-00001.
- Wiernik PH, Duncan JH. Cyclophosphamide in human milk. Lancet. May 1971, 1 (7705): 912. PMID 4102054. doi:10.1016/s0140-6736(71)92474-3.
- Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism & Toxicology. August 2010, 6 (8): 919–938. PMID 20446865. S2CID 695545. doi:10.1517/17425255.2010.487861.
- Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney International. April 2002, 61 (4): 1495–501. PMID 11918757. doi:10.1046/j.1523-1755.2002.00279.x .
- Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. Bone Marrow Transplantation. December 1999, 24 (12): 1367–8. PMID 10627651. S2CID 22946564. doi:10.1038/sj.bmt.1702097.
- Vigouroux D, Voltaire L. [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide] [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]. Annales Françaises d'Anesthésie et de Réanimation. 1995, 14 (6): 508–10. PMID 8745976. doi:10.1016/S0750-7658(05)80493-9. INIST:2947795 （法语）.
- Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Reviews. September 1992, 6 (3): 163–73. PMID 1422285. doi:10.1016/0268-960X(92)90028-O.
- Kohn FR, Sladek NE. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochemical Pharmacology. October 1985, 34 (19): 3465–71. PMID 2996550. doi:10.1016/0006-2952(85)90719-1.
- Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in Immunopathology. July 2011, 33 (4): 369–83. PMID 21611872. S2CID 3360104. doi:10.1007/s00281-011-0245-0.
- Friedman OM, Seligman AM. Preparation of N-Phosphorylated Derivatives of Bis-β-chloroethylamine1a. Journal of the American Chemical Society. 1954, 76 (3): 655–8. Bibcode:1954JAChS..76..655F. doi:10.1021/ja01632a006.
- Colvin OM. An overview of cyclophosphamide development and clinical applications. Current Pharmaceutical Design. August 1999, 5 (8): 555–60. PMID 10469891. doi:10.2174/1381612805666230110214512.
- Brock N. The history of the oxazaphosphorine cytostatics. Cancer. August 1996, 78 (3): 542–7. PMID 8697402. doi:10.1002/(SICI)1097-0142(19960801)78:3<542::AID-CNCR23>3.0.CO;2-Y .
- Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infectious Diseases. March 2006, 6 (1): 55. PMC 1434751 . PMID 16545113. doi:10.1186/1471-2334-6-55 （英语）.
- Huyan XH, Lin YP, Gao T, Chen RY, Fan YM. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. International Immunopharmacology. September 2011, 11 (9): 1293–7. PMID 21530682. doi:10.1016/j.intimp.2011.04.011.
drugs.com
- Cyclophosphamide. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2017-01-02）.
epa.gov
google.com
handle.net
hdl.handle.net
- World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
harvard.edu
ui.adsabs.harvard.edu
- Friedman OM, Seligman AM. Preparation of N-Phosphorylated Derivatives of Bis-β-chloroethylamine1a. Journal of the American Chemical Society. 1954, 76 (3): 655–8. Bibcode:1954JAChS..76..655F. doi:10.1021/ja01632a006.
inist.fr
pascal-francis.inist.fr
- Vigouroux D, Voltaire L. [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide] [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]. Annales Françaises d'Anesthésie et de Réanimation. 1995, 14 (6): 508–10. PMID 8745976. doi:10.1016/S0750-7658(05)80493-9. INIST:2947795 （法语）.
ismp.org
- Institute for Safe Medication Practices, ISMP's List of Error-Prone Abbreviations, Symbols, and Dose Designations (PDF), （原始内容存档 (PDF)于2011-10-27）.
medicinescomplete.com
- Brayfield, A (编). Cyclophosphamide: Martindale: The Complete Drug Reference. MedicinesComplete. London, UK: Pharmaceutical Press. 2017-01-09 [2017-08-12].
merriam-webster.com
nih.gov
ncbi.nlm.nih.gov
- Pagnoux C. Updates in ANCA-associated vasculitis. European Journal of Rheumatology. September 2016, 3 (3): 122–133. PMC 5058451 . PMID 27733943. doi:10.5152/eurjrheum.2015.0043.
- DeVrieze BW, Hurley JA. Goodpasture Syndrome (Anti-glomerular Basement Membrane Antibody Disease). StatPearls. Treasure Island, USA: StatPearls Publishing. 2019. PMID 29083697.
- La Mantia L, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. The Cochrane Database of Systematic Reviews. January 2007, 2007 (1): CD002819. PMC 8078225 . PMID 17253481. doi:10.1002/14651858.CD002819.pub2.
- Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology. April 2017, 56 (suppl_1): i100–i113. PMC 5850311 . PMID 28375452. doi:10.1093/rheumatology/kew417.
- Singh JA, Hossain A, Kotb A, Wells GA. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Systematic Reviews. September 2016, 5 (1): 155. PMC 5020478 . PMID 27619512. doi:10.1186/s13643-016-0328-z .
- Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American Journal of Hematology. December 2014, 89 (12): 1132–40. PMID 25407896. S2CID 85480421. doi:10.1002/ajh.23828.
- Or-Geva N, Reisner Y. The evolution of T-cell depletion in haploidentical stem-cell transplantation. British Journal of Haematology. March 2016, 172 (5): 667–84. PMID 26684279. S2CID 1093277. doi:10.1111/bjh.13868 .
- Fuchs EJ. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplantation. June 2015, 50 (Suppl 2): S31–6. PMC 4634886 . PMID 26039204. doi:10.1038/bmt.2015.92.
- Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Seminars in Hematology. April 2016, 53 (2): 90–7. PMC 4806368 . PMID 27000732. doi:10.1053/j.seminhematol.2016.01.005.
- Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?. American Journal of Medical Genetics. September 1999, 86 (3): 237–41. PMID 10482872. doi:10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V .
- Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. The Journal of Rheumatology. February 1991, 18 (2): 188–94. PMID 1673721.
- Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984, 41 (3): 180–4. PMID 6374556. doi:10.1159/000225819.
- Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Medicine. September 2016, 14 (1): 137. PMC 5022202 . PMID 27623861. doi:10.1186/s12916-016-0673-8 .
- Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clinics in Chest Medicine. March 1990, 11 (1): 31–54. PMID 1691069. doi:10.1016/S0272-5231(21)00670-5.
- Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. American Journal of Respiratory and Critical Care Medicine. December 1996, 154 (6 Pt 1): 1851–6. PMID 8970380. doi:10.1164/ajrccm.154.6.8970380.
- Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. Journal of Clinical Oncology. October 2005, 23 (30): 7685–96. PMID 16234530. doi:10.1200/JCO.2005.08.789.
- Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Archives of Internal Medicine. March 1985, 145 (3): 548–9. PMID 3977522. doi:10.1001/archinte.145.3.548.
- Salido M, Macarron P, Hernández-García C, D'Cruz DP, Khamashta MA, Hughes GR. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus. 2003, 12 (8): 636–9. PMID 12945725. S2CID 26125211. doi:10.1191/0961203303lu421cr.
- Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Reviews. Clinical Oncology. November 2009, 6 (11): 638–47. PMID 19786984. S2CID 18219134. doi:10.1038/nrclinonc.2009.146.
- Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis and Rheumatism. January 2010, 62 (1): 9–21. PMID 20039416. doi:10.1002/art.25061.
- Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. September 1992, 340 (8822): 741–5. PMID 1356175. S2CID 8800101. doi:10.1016/0140-6736(92)92292-n.
- Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis and Rheumatism. September 1996, 39 (9): 1475–82. PMID 8814058. doi:10.1002/art.1780390906.
- Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis and Rheumatism. July 2008, 59 (7): 1034–9. PMID 18576286. doi:10.1002/art.23822.
- Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. European Journal of Clinical Investigation (Review). March 2015, 45 (3): 346–68. PMID 25627555. S2CID 870510. doi:10.1111/eci.12410 .
- Balow JE, Austin HA, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH. NIH conference. Lupus nephritis. Annals of Internal Medicine. January 1987, 106 (1): 79–94. PMID 3789582. doi:10.7326/0003-4819-106-1-79.
- Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clinical Pharmacokinetics. 2002, 41 (7): 485–504. PMID 12083977. S2CID 10873321. doi:10.2165/00003088-200241070-00003.
- Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Archives of Internal Medicine. February 2008, 168 (4): 378–81. PMID 18299492. doi:10.1001/archinternmed.2007.107 .
- Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Kwoh CK. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis and Rheumatism. August 1995, 38 (8): 1120–7. PMID 7639809. doi:10.1002/art.1780380815.
- Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology. American Society of Hematology. Education Program. 2007, 2007: 453–9. PMID 18024664. doi:10.1182/asheducation-2007.1.453 .
- Cohen JL, Jao JY. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. The Journal of Pharmacology and Experimental Therapeutics. August 1970, 174 (2): 206–10 [2014-05-02]. PMID 4393764. （原始内容存档于2021-08-28）.
- Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design. Pharmacological Reviews. September 2011, 63 (3): 750–71. PMID 21737530. S2CID 25381232. doi:10.1124/pr.110.003459.
- Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clinical Pharmacokinetics. April 2000, 38 (4): 291–304. PMID 10803453. S2CID 39787288. doi:10.2165/00003088-200038040-00001.
- Wiernik PH, Duncan JH. Cyclophosphamide in human milk. Lancet. May 1971, 1 (7705): 912. PMID 4102054. doi:10.1016/s0140-6736(71)92474-3.
- Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism & Toxicology. August 2010, 6 (8): 919–938. PMID 20446865. S2CID 695545. doi:10.1517/17425255.2010.487861.
- Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney International. April 2002, 61 (4): 1495–501. PMID 11918757. doi:10.1046/j.1523-1755.2002.00279.x .
- Donelli MG, Bartosek I, Guaitani A, Martini A, Colombo T, Pacciarini MA, Modica R. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect. Cancer Treatment Reports. April 1976, 60 (4): 395–401. PMID 1277213.
- Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. Bone Marrow Transplantation. December 1999, 24 (12): 1367–8. PMID 10627651. S2CID 22946564. doi:10.1038/sj.bmt.1702097.
- Vigouroux D, Voltaire L. [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide] [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]. Annales Françaises d'Anesthésie et de Réanimation. 1995, 14 (6): 508–10. PMID 8745976. doi:10.1016/S0750-7658(05)80493-9. INIST:2947795 （法语）.
- Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Reviews. September 1992, 6 (3): 163–73. PMID 1422285. doi:10.1016/0268-960X(92)90028-O.
- Kohn FR, Sladek NE. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochemical Pharmacology. October 1985, 34 (19): 3465–71. PMID 2996550. doi:10.1016/0006-2952(85)90719-1.
- Friedman OM, Wodinsky I, Myles A. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective. Cancer Treatment Reports. April 1976, 60 (4): 337–46. PMID 1277209.
- Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in Immunopathology. July 2011, 33 (4): 369–83. PMID 21611872. S2CID 3360104. doi:10.1007/s00281-011-0245-0.
- Colvin OM. An overview of cyclophosphamide development and clinical applications. Current Pharmaceutical Design. August 1999, 5 (8): 555–60. PMID 10469891. doi:10.2174/1381612805666230110214512.
- Brock N. The history of the oxazaphosphorine cytostatics. Cancer. August 1996, 78 (3): 542–7. PMID 8697402. doi:10.1002/(SICI)1097-0142(19960801)78:3<542::AID-CNCR23>3.0.CO;2-Y .
- Brock N. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Research. January 1989, 49 (1): 1–7. PMID 2491747.
- Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infectious Diseases. March 2006, 6 (1): 55. PMC 1434751 . PMID 16545113. doi:10.1186/1471-2334-6-55 （英语）.
- Huyan XH, Lin YP, Gao T, Chen RY, Fan YM. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. International Immunopharmacology. September 2011, 11 (9): 1293–7. PMID 21530682. doi:10.1016/j.intimp.2011.04.011.
pmc.ncbi.nlm.nih.gov
- King, Catherine; Harper, Lorraine. Avoidance of Harm From Treatment for ANCA-Associated Vasculitis. Current Treatment Options in Rheumatology. 2017-11-13, 3 (4): 230–243 [2025-02-27]. doi:10.1007/s40674-017-0082-y.
oxforddictionaries.com
- cyclophosphamide – definition of cyclophosphamide in English from the Oxford dictionary. OxfordDictionaries.com. [2016-01-20]. （原始内容存档于2012-08-25）.
semanticscholar.org
api.semanticscholar.org
- Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American Journal of Hematology. December 2014, 89 (12): 1132–40. PMID 25407896. S2CID 85480421. doi:10.1002/ajh.23828.
- Or-Geva N, Reisner Y. The evolution of T-cell depletion in haploidentical stem-cell transplantation. British Journal of Haematology. March 2016, 172 (5): 667–84. PMID 26684279. S2CID 1093277. doi:10.1111/bjh.13868 .
- Salido M, Macarron P, Hernández-García C, D'Cruz DP, Khamashta MA, Hughes GR. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus. 2003, 12 (8): 636–9. PMID 12945725. S2CID 26125211. doi:10.1191/0961203303lu421cr.
- Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Reviews. Clinical Oncology. November 2009, 6 (11): 638–47. PMID 19786984. S2CID 18219134. doi:10.1038/nrclinonc.2009.146.
- Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. September 1992, 340 (8822): 741–5. PMID 1356175. S2CID 8800101. doi:10.1016/0140-6736(92)92292-n.
- Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. European Journal of Clinical Investigation (Review). March 2015, 45 (3): 346–68. PMID 25627555. S2CID 870510. doi:10.1111/eci.12410 .
- Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clinical Pharmacokinetics. 2002, 41 (7): 485–504. PMID 12083977. S2CID 10873321. doi:10.2165/00003088-200241070-00003.
- Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design. Pharmacological Reviews. September 2011, 63 (3): 750–71. PMID 21737530. S2CID 25381232. doi:10.1124/pr.110.003459.
- Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clinical Pharmacokinetics. April 2000, 38 (4): 291–304. PMID 10803453. S2CID 39787288. doi:10.2165/00003088-200038040-00001.
- Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism & Toxicology. August 2010, 6 (8): 919–938. PMID 20446865. S2CID 695545. doi:10.1517/17425255.2010.487861.
- Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. Bone Marrow Transplantation. December 1999, 24 (12): 1367–8. PMID 10627651. S2CID 22946564. doi:10.1038/sj.bmt.1702097.
- Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in Immunopathology. July 2011, 33 (4): 369–83. PMID 21611872. S2CID 3360104. doi:10.1007/s00281-011-0245-0.
web.archive.org
- cyclophosphamide – definition of cyclophosphamide in English from the Oxford dictionary. OxfordDictionaries.com. [2016-01-20]. （原始内容存档于2012-08-25）.
- NCI Drug Dictionary. National Cancer Institute. 2011-02-02 [2016-12-20]. （原始内容存档于2015-04-25）.
- Cyclophosphamide. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2017-01-02）.
- Cohen JL, Jao JY. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. The Journal of Pharmacology and Experimental Therapeutics. August 1970, 174 (2): 206–10 [2014-05-02]. PMID 4393764. （原始内容存档于2021-08-28）.
- Institute for Safe Medication Practices, ISMP's List of Error-Prone Abbreviations, Symbols, and Dose Designations (PDF), （原始内容存档 (PDF)于2011-10-27）.
- EPA: Notifications, FY 1998 to Present - Biotechnology Program under the Toxic Substances Control Act (TSCA) | New Chemicals Program | US EPA. [2015-07-01]. （原始内容存档于2015-06-21）.
webmd.com
- Cyclophosphamide Vial - Uses, Side Effects, and More. WebMD. [2025-02-28].
wikipedia.org
fr.wikipedia.org
- Vigouroux D, Voltaire L. [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide] [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]. Annales Françaises d'Anesthésie et de Réanimation. 1995, 14 (6): 508–10. PMID 8745976. doi:10.1016/S0750-7658(05)80493-9. INIST:2947795 （法语）.
worldcat.org
- Wilmanns H. Chemotherapie maligner Tumoren [Chemotherapy of malignant tumors]. Asta-Forschung und Therapie. 1958. OCLC 73296245 （德语）.[页码请求]
zenodo.org
- Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. September 1992, 340 (8822): 741–5. PMID 1356175. S2CID 8800101. doi:10.1016/0140-6736(92)92292-n.
- Huyan XH, Lin YP, Gao T, Chen RY, Fan YM. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. International Immunopharmacology. September 2011, 11 (9): 1293–7. PMID 21530682. doi:10.1016/j.intimp.2011.04.011.